Despite the challenges of balancing antileukemic efficacy with preservation of normal cellular metabolism, the identification of specific metabolic vulnerabilities of FLT3-mutated leukemia cells opens new avenues for targeted therapeutic strategies. The gene discussed is FLT3; the disease is leukemia.